Repare Therapeutics Inc. (RPTX): Price and Financial Metrics
RPTX Price/Volume Stats
| Current price | $3.47 | 52-week high | $13.85 |
| Prev. close | $3.65 | 52-week low | $3.08 |
| Day low | $3.35 | Volume | 89,800 |
| Day high | $3.71 | Avg. volume | 147,089 |
| 50-day MA | $5.75 | Dividend yield | N/A |
| 200-day MA | $7.29 | Market Cap | 128.39M |
RPTX Stock Price Chart Interactive Chart >
Repare Therapeutics Inc. (RPTX) Company Bio
Repare Therapeutics, Inc. engages in the research, development, and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations. The company was founded by Daniel Durocher, Agnel Sfeir and Frank Sicheri on September 6, 2016 and is headquartered in Saint-Laurent, Canada.
Latest RPTX News From Around the Web
Below are the latest news stories about REPARE THERAPEUTICS INC that investors may wish to consider to help them evaluate RPTX as an investment opportunity.
Repare Therapeutics (RPTX) Rises 34% in a Week: Here's WhyRepare Therapeutics (RPTX) rises 34% in a week after announcing plans to begin clinal-stage development of two additional candidates, RP-1664 and RP-3467, in 2024 in several solid tumor indications. |
Repare Therapeutics Unveils Two Programs Expected to Enter Clinical Trials in 2024: RP-1664, an Oral PLK4 Inhibitor, and RP-3467, an Oral Polθ InhibitorCAMBRIDGE, Mass. & MONTREAL, November 15, 2023--Repare Therapeutics Inc. ("Repare" or the "Company") (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today disclosed polo-like kinase 4 (PLK4) as the target of its RP-1664 development program and reported comprehensive preclinical data for both RP-1664 and the Company’s Polθ inhibitor, RP-3467. |
Repare Therapeutics Inc. (NASDAQ:RPTX) most popular amongst private equity firms who own 33% of the shares, institutions hold 28%Key Insights The considerable ownership by private equity firms in Repare Therapeutics indicates that they collectively... |
These Biotech Stocks Could Double Your Money, According To AnalystsThe biotech industry has been in the limelight since the COVID-19 pandemic, with public and private sectors pouring in funds to bolster innovation and the development of relevant drugs. Approximately 63% of public biotech firms reported revenue growth in 2021. Emerging biotech companies, which have annual revenue below $500 million, recorded a median 40% annual revenue growth rate, outpacing industry giants, which reported a lower 35% average annual revenue growth rate. While the pandemic-relate |
Repare Therapeutics Inc (RPTX) Reports Q3 2023 Financial Results Amid Pipeline ProgressInitial Positive Data from MYTHIC Trial and Preclinical Program Updates |
RPTX Price Returns
| 1-mo | -34.40% |
| 3-mo | -43.49% |
| 6-mo | -23.23% |
| 1-year | -63.47% |
| 3-year | -89.70% |
| 5-year | N/A |
| YTD | -52.47% |
| 2023 | -50.37% |
| 2022 | -30.25% |
| 2021 | -38.51% |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...